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Abstract
Objectives Clinical trials provide one of the highest levels of evidence to support medical practice. Investigator initiated 
clinical trials (IICTs) answer relevant questions in clinical practice that may not be addressed by industry. For the first time, 
two European Countries are compared in terms of IICTs, respective funders and publications, envisaging to inspire others 
to use similar indicators to assess clinical research outcomes.
Methods A retrospective systematic search of registered IICTs from 2004 to 2017, using four clinical trials registries was 
carried out in two European countries with similar population, GDP, HDI and medical schools but with different govern-
mental models to fund clinical research. Each IICT was screened for sponsors, funders, type of intervention and associated 
publications, once completed.
Results IICTs involving the Czech Republic and Portugal were n = 439 (42% with hospitals as sponsors) and n = 328 (47% 
with universities as sponsors), respectively. The Czech Republic and Portuguese funding agencies supported respectively 
61 and 27 IICTs. Among these, trials with medicinal products represent 52% in Czech Republic and 4% in Portugal. In the 
first, a higher percentage of IICTs’ publications in high impact factor journals with national investigators as authors was 
observed, when compared to Portugal (75% vs 15%).
Conclusion The better performance in clinical research by Czech Republic might be related to the existence of specific and 
periodic funding for clinical research, although further data are still needed to confirm this relationship. In upcoming years, 
the indicators used herein might be useful to tracking clinical research outcomes in these and other European countries.
Keywords Investigator initiated clinical trials · Funding · Clinical trials registry · Clinical research · Clinical trial · Clinical 
research outcome
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Introduction
In the last decades, clinical research played a crucial role on 
increasing the medical knowledge for the prevention, diag-
nostic, treatment and cure of diseases. Clinical trials pro-
vide one of the highest levels of evidence to support medical 
practice and might be initiated by the industry or by clinical 
investigators. The latter, commonly called investigator-ini-
tiated clinical trials (IICTs), are interventional studies using 
medicinal products, medical devices, surgery techniques, 
behavior testing or several types of procedures. These trials 
are pivotal to generate relevant and unbiased data decisive 
for the implementation of new therapies and better-informed 
decisions by health regulators [1]. However, the importance 
and relevance of IICTs rely heavily on its independence and 
impartiality, which in turn is directly linked to the fund-
ing source. Some IICTs are funded by industry, which can 
introduce a bias in the outcome of these studies. In fact, a 
systematic review of 1140 studies demonstrated that indus-
try-sponsored clinical trials were significantly more likely to 
reach conclusions favorable to the sponsors than those who 
were not industry-sponsored trials [2].
Therefore, public national funding agencies have a criti-
cal role on supporting fully independent clinical research 
with the sole purpose of benefiting the large patients´ popu-
lation through the improvement of medical knowledge. 
Public funding of IICTs can also play an important role on 
addressing important clinical questions that remain unre-
solved because they are not addressed in industry-funded 
trials. Crowe and colleagues showed that there is an impor-
tant mismatch on clinical research priorities identified by the 
patients and the clinicians, which in part is affected by the 
commercial aspect of clinical research [3].
The unbalanced ratio between private and public funding 
of IICTs (and its impact on national health systems through 
the definition of public policies for the treatment of diseases) 
is particularly relevant in countries with negligible expendi-
ture in this area, which is usually associated to limited funds 
for the promotion of clinical research. It is important to gen-
erate significant scientific data to be able to provide bet-
ter and informed guidance for the funding of IICTs by the 
national public funding agencies.
The Czech Republic and Portugal have similar popula-
tion numbers (10.6 million and 10.3 million, respectively), 
GDP per capita (€14.8 thousand and €16.9 thousand, respec-
tively), Human Development Index (2017: 0.896 and 0.858, 
respectively) and number of Medical Schools (n = 9 and 
n = 8, respectively), which makes them comparable countries 
for such study. In a previous publication, and considering 
only clinical trial registries in the European Clinical Trials 
Registry (EU-CTR) it was shown that Czech Republic and 
Portugal are both below the average among all European 
countries in what regards the percentage of IICT/Total CT 
(5% and 8%, respectively) [4].
Both countries are members of the European Union and 
thus have access to the same funding schemes and also 
operating under to the same health regulatory environment 
(supervised by the European Medicines Agency). Addition-
ally, both countries are members of the European Clinical 
Research Infrastructure Network (ECRIN-ERIC), which is 
a public, non-profit organisation committed in supporting 
and facilitating multinational independent clinical trials in 
Europe.
Currently, the Czech Clinical Research Infrastructure 
Network (CZECRIN) aims its activities to bring together 
academic research institutes, scientists and policymakers in 
discussion on issues related, particularly public funding of 
the clinical research in the Czech Republic. CZECRIN’s spe-
cific goal is to promote and support academic research on the 
national basis and the integration of national investigators in 
multinational clinical studies.
The Portuguese Clinical Research Infrastructure Net-
work (PtCRIN) has been developing several national studies 
where the status of IICTs in Portugal were assessed [4, 5]. 
Despite the relevance of such data to define national strate-
gies for this area, the impact of such analysis can be maxi-
mized through a comprehensive benchmarking with other 
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European countries, particularly the ones with similar char-
acteristics. Therefore, intending to perform a comprehensive 
assessment of the current situation, this study analyzed the 
type of registered IICTs in the Czech Republic and in Por-
tugal and for the first time unveiled the differences in terms 
of funding policies and scientific outcome.
Methods
We identified past or current IICTs registered and starting 
in two European countries (Czech Republic and Portugal) 
from 01/01/2004 to 31/12/2017 to identify detailed studies´ 
characteristics such as the funding sources and the respec-
tive scientific impact. This period of time starts in the year 
after which the International Committee of Medical Journal 
Editors’ implementation (ICMJE), policy required the regis-
tration of clinical trials as a prerequisite for consideration for 
publication (2004) until the end of 2017. A separate search 
in four clinical trial registries (CTRs) was performed for 
each country: ClinicalTrials.gov, European Clinical Trials 
Registry (EU-CTR), International Standard Randomised 
Controlled Trial Number (ISRCTN) registry, and the Aus-
tralian New Zealand Clinical Trials Registry (ANZCTR) 
by selecting trials registered and with recruitment sites in 
Czech Republic or Portugal. These CTRs encompass 81% 
of the registrations uploaded to the International Clinical 
Trials Registry Platform (ICTRP) from WHO, according 
to the information provided by others [6]. Furthermore, we 
collected and compared the national public policies imple-
mented by the Portuguese and Czech governments to pro-
mote clinical research during this timeframe.
Search Methodology for Clinical Trials Identification 
in Each Database
The inclusion criteria were: clinical trial starting from 
01/01/2004 until 31/12/2017; non-commercial sponsor; 
sponsor or recruiting sites in Portugal or in Czech Repub-
lic. The following exclusion criteria were used: industry 
sponsored trials; starting date before 01/01/2004; sponsor 
or recruitment site not involving the Czech Republic or Por-
tugal; non-intervention trials.
Step 1: The search in the EU-CTR allowed to include 
as general term “non-commercial” therefore eliminating 
the commercial studies. The timeframe selected was from 
01/01/2004 until 31/12/2017 as well as the countries, the 
Czech Republic or Portugal. No other requirement in the 
advanced search field was selected.
Step 2: As the discrimination between commercial and 
non-commercial clinical trial is not possible at the Clinical-
Trials.gov platform, an advanced search was performed. The 
IICTs were extracted by selecting the predefined options: 
“Interventional studies”, the above-mentioned time period, 
each one of the countries, restricting to: NIH (U.S. National 
Institutes of Health), Other U.S. Federal agency, all others 
(individuals, universities, organizations) and Industry were 
chosen.
Step 3: Registrations in the BiomedCentral CTR are 
associated with ISRCTN. In this CTR it was not possible to 
refine the search with the exception of selecting the Czech 
Republic or Portugal as the recruiting country. Trials initi-
ated before or after the referred timeframe were discarded.
Step 4: In the ANZCTR, we performed the search in the 
selected timeframe, using the Czech Republic or Portugal 
as the recruiting country. Registrations in this CTR have the 
initial code ACTRN.
The search results were reviewed individually by two 
independent experts in each national team to confirm the 
compliance with the inclusion and exclusion criteria.
Data Extraction, Duplicates and Complementary 
Information
Step 5: Information about trial identification (Trial ID) num-
ber (main and secondary), recruitment status, sponsor name 
and country, trial title, trial phase (when applicable), type of 
intervention, therapeutic area, type of funding and publica-
tions of the completed studies, were extracted manually and 
independently from the registered records (from 1/03/2018 
to 31/08/2018), gathered and organized in an Excel sheet 
for each country. No restrictions on each of the referred 
information was applied. Forty percent of the records were 
double-checked by two individuals from each team and dis-
cussed until a consensus was reached.
Step 6: Duplicates were identified in each database, when 
secondary IDs were provided or when the sponsor and the 
study title were the same. The same study registered in dif-
ferent CTRs was considered duplicated and removed at this 
point of the search. When complementary information was 
provided in different registrations about the same study it 
was added to the respective entry in the working Excel sheet. 
None of the studies identified had recruitment sites in both 
countries, so no clinical trial is considered in both databases.
Sponsors were coded as: Disease-Specific Organization 
(Disease associations or research institutes dedicated to a 
specific therapeutic area), Foundation (Research Institutes 
or Health Institutions legally constituted as foundations), 
Hospital, Research Institutes (non-specific therapeutic 
area), University, and others (Private health clinic, Funder 
Agency, acting as sponsor). In the four CTRs, the funding 
source was identified in different fields. Both in ISRCTN 
and ANZCTR there is a specific field entitled “Funder”. 
In Clinicaltrials.gov CTR the funders were identified from 
the field “Sponsor and Collaborators”. In EU-CTR the 
funder was identified in the field “sources of monetary 
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support “. All the funders identified in these CTRs were 
classified as: (i) Public organizations (non-profit organiza-
tion such as public institutions, funding agencies, disease 
specific organizations); (ii) Private organization (for-profit 
organization—Industry); (iii) Both, when the funding is 
provided by the industry and one or more public organi-
zations; (iv) Not Indicated, when the information was not 
provided in any registry or in the publication.
When only the sponsor was mentioned in the Clinical-
Trials.gov registry, we considered it as the funder. The 
support of funding agencies was perceived through sec-
ondary IDs where the code of the grant agreement is in 
some cases added. Exclusive funding for PhD or Post-
Doctoral grants was not considered.
Search of Publications of Completed IICTs
Step 7: Information regarding the publications of the reg-
istered and completed IICTs were manually and indepen-
dently screened. The Trial ID was used to search abstracts 
of journals indexed in Medline (using PubMed) as well 
as in the four CTRs. By the principal investigator´s name 
was possible to identify publications, when no paper was 
found with the previous strategies. In some publications, 
the Trial ID was not included in the abstract, which ren-
dered the search more difficult. All completed trials and 
published until 31/12/2017 were considered for further 
analysis. Subsequently, screening of each publication was 
performed to complete the information about the funding 
sources of IICTs to identify any other relevant information 
that was not complete in CTRs. The journal’s impact fac-
tor was obtained from Web of Science, Research Gate or 
Bioxbio.com, considering this order when different impact 
factors for the year of publication were found for the same 
journal. The citation number since the year of publication 
up to 1 year after the paper was published was assessed 
through Pubmed metrics. Around 40% of the data were 
mutually exchanged between Czech and Portuguese team 
and double checked by two independent reviewers.
Results
A total of 3496 and 1427 registrations were found in the 
four CTRs involving the Czech Republic and Portuguese 
institutions, respectively: ClinicalTrials.gov, EU-CTR, 
ISRCTN, and ANZCTR. Clinical trials were screened 
to isolate those with a non-commercial sponsor, recruit-
ing sites in Czech Republic or Portugal, and a start date 
between 01/01/2004 and 31/12/2017.
Identification of Non‑commercial Studies
The total number of trials for Czech Republic and Portugal, 
identified in all databases is respectively 3496 and 1427 as 
shown in Fig. 1. After discarding industry sponsored tri-
als, non-interventional studies, or those with no recruiting 
sites in the Czech Republic or Portugal, 485 and 378 non-
commercial trials (i.e. IICTs) were respectively considered 
eligible from all the screened databases. The same trial 
registered in different CTRs was separated and considered 
as duplicate. After discarding duplicates, a total number 
of 439 IICTs were identified involving the Czech Repub-
lic whereas for Portugal 328 trials were found. Forty-one 
percent (n = 180/439) and 44% (n = 144/328) of the studies 
were already completed and from those 41% (n = 73/180) 
and 55% (n = 79/144) were published, in the Czech Republic 
and Portugal, respectively.
Characteristics of IICTs in the Czech Republic 
and in Portugal
In both countries, most of IICTs has a national sponsor and 
were performed in the respective country (Fig. 2a). These 
IICTs, with national sponsors are those initiated by investi-
gators from each of these countries. Only a low percentage 
of IICTs with national sponsor are also multinational trials 
(implemented in other countries)—6% in the Czech Repub-
lic (n = 15/257) and 4% in Portugal (n = 8/193).
Regarding the international trials which are those initi-
ated by investigators from other countries and conducted in 
The Czech Republic or in Portugal, both countries have also 
the same percentage (41%; n = 182/439 and n = 135/328) 
(Fig. 2a).
In the Czech Republic, most trials´ sponsors (42%; 
n = 183/439) were hospitals while in Portugal, universi-
ties assume the sponsorship in higher number of trials 
when compared to the other types of organizations (47%; 
n = 153/328) (Fig. 2b).
Figure 2c shows that trials with hospitals as the sponsor 
were testing investigational medicinal products (IMPs) (46% 
(n = 84/183), and 45% (n = 32/71), respectively in the Czech 
Republic and Portugal), medical devices (16% (n = 30/183), 
and 20% (n = 14/71), respectively in Czech Republic and 
Portugal) and behavior (2% (n = 4/183), and 13% (n = 9/71), 
respectively in the Czech Republic and Portugal). Regarding 
all trials sponsored by universities, 62% (n = 94/150) test 
IMPs in the Czech Republic, whereas in Portugal, the larg-
est group by intervention type, 49% (n = 75/153), focuses 
on behavior (Fig. 2b, c). The percentage of trials with IMPs 
in phase III trials is quite similar in both countries: 32%, 
(n = 82/258) in the Czech Republic and 39% (n = 54/136) 
in Portugal (Supplementary Information 1 (S1), Fig. 1a, 
a1). Additionally, the two most focused therapeutic areas of 
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the interventional studies are the same: oncology and car-
diovascular diseases, followed by gastroenterology in the 
Czech Republic and musculoskeletal disorders in Portugal 
(S1, Fig. 1b, c).
IICTs in both countries are mainly funded by public 
organizations (Fig. 2d) such as universities, hospitals, 
disease specific organizations, foundations and fund-
ing agencies: 78% (n = 343/439) in the Czech Republic 
and 69% (n = 226/328) in Portugal. Considering all types 
of interventions funded by public organizations, 50% 
(n = 173/343) are trials with IMPs in the Czech Republic 
Figure 1  Flowchart Showing the Systematic Search of Non-commer-
cial Clinical Trials (i.e. IICTs), Involving the Czech Republic and 
Portuguese Institutions Recruiting Participants. The search was per-
formed in four clinical trial registries, CTRs (EU-CTR, Clinicaltrials.
gov, ISRCTN and ANZCTR). Studies starting from 01/01/2004 until 
31/12/2017 were identified in each of the databases separately (Steps 
1–4). After discarding commercial trials all remaining studies were 
gathered in one Excel sheet for each country (Step 5). Duplicate stud-
ies were also discarded, and the final number of trials was cleaned 
and harmonized (Step 6). Further details were collected from all the 
databases, including the identification of completed studies. Publica-
tions published until December 2017, with results from completed 
studies were identified (Step 7).
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and only 27% (n = 60/226) in Portugal. In the latter, most 
trials funded by public organizations, 36% (n = 82/226), 
are behavior-based (Fig. 2d, e). Details about each registry 
are provided as Supplementary Information 2 (S2).
Figure 2  Characteristics of IICTs in the Czech Republic and in Por-
tugal. Number of trials according to the sponsor (national vs inter-
national) and to the involvement of other countries in national 
sponsored trials (national vs multinational trial) (a); Percentage and 
number of trials according to the type of sponsor organization (b) 
and number of trials according to the type of most frequent interven-
tions sponsored by universities or hospitals (n = 243 out of 333 for the 
Czech Republic and n = 177 out of 224 for Portugal) (c); Percentage 
and number of trials according to the type of funder (d) and number 
of trials according to the type of most frequent intervention funded 
by public or private organizations (n = 260 out of 365 for the Czech 
Republic and n = 201 out of 257 for Portugal) (e).
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Clinical Trials Funded by National and International 
Funding Agencies
One of the greatest public funders of the IICTs in both 
countries were funding agencies (national and interna-
tional) corresponding to 29% (n = 109/381) and 21% 
(n = 60/282) of the public funding in the Czech Repub-
lic and in Portugal, respectively. The total number of tri-
als indicated above (381 and 282) refers to those funded 
by public organizations alone or together with private 
institutions (Fig.  2d: Public and Both). From the 109 
IICTS trials funded by governmental agencies in the Czech 
Republic 65% (n = 71/109) of the trials were funded by 
national funding grant agencies while the remaining 35% 
(n = 38/109) IICTs were funded by international counter-
parts (Fig. 3a). Figure 3a shows that in this country both 
national and international agencies mainly fund trials with 
IMPs. Among the 61 trials funded by the Czech Health 
Research Council (Table 1), 32 (52%, n = 32/61) are test-
ing medicinal products (data not shown).
Figure 3  Characteristics of IICTs Funded by Funding Agencies. Number of trials funded with national or international funding agencies in the 
Czech Republic (a) and in Portugal (b), according to the type of intervention and sponsor.
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On the other hand, among the 60 IICTs in Portugal 
receiving financial support from funding grant agencies, 
only half of these (50%, n = 30/60) were funded by national 
funding grant agencies or funding programs (Fig. 3b) 
while the other half was funded by international funding 
agencies. Among the 27 trials funded by Fundação para 
a Ciência e Tecnologia (Table 1) only one (4%, n = 1/27) 
is testing medicinal products (data not shown). During the 
time period studied in the present work, FCT launched 
only one call, in 2007, specifically focused in clinical 
research. The Ministry of Health had a financial contri-
bution to this call and a total amount of 9 M € were used 
to fund 63 projects [7]. However, none of these funded 
studies were found in our search, probably because most 
of them were not interventional studies or interventional 
without IMPs which registration is desirable but not man-
datory. Nevertheless, screening the information provided 
by FCT we found at least one interventional study with 
IMP that was not properly classified, consequently not reg-
istered in a database by the investigators [8].
The level of participation of Czech Republic and Portu-
gal in international grants was similar (n = 38 and n = 30, 
respectively), most of these involving trials with IMPs in 
both cases (Fig. 3a, b). The organizations receiving national 
funds, thus acting as sponsor, in higher number of trials in 
the Czech Republic were hospitals (32%: n = 35/109) and 
universities (22%: n = 24/109). Whereas in Portugal were 
the universities (40%: n = 24/60) that sponsored more trials 
funded by national funding agencies followed by hospitals 
(7%: n = 4/60). Portuguese hospitals sponsored more trials 
funded by international funding grants then with national 
funding grant agencies (n = 8 vs n = 4).
Table 1 shows all the funding grant agencies identified 
both in the registries and in the publications for each com-
pleted and published clinical trial. In the Czech Republic 
there were a higher number of trials funded by national 
funding agencies and the number of registrations is gradu-
ally growing every year since 2004 (S1, Fig. 1d–e). When 
compared to the Czech Republic, a lower number of funded 
IICTs by public funding agencies were identified in Portugal, 
however, the national investigators have been involved in 
trials with more diverse funding opportunities, especially 
international ones.
In the Czech Republic, University hospitals are pressured 
to apply to grant support and carry out clinical research, 
because most physicians working in the hospital are univer-
sity employees at the same time and need to build up their 
career as researchers. Moreover, there is a lack of experi-
enced grant offices in the Czech Republic which would help 
the investigators to prepare an application for international 
grant call, e.g. H2020, IMI2. However, the mandatory insur-
ance to initiate a clinical trial with medicines is not eligible 
in these grants´ call which might hamper the initiation of 
more trials. In theory, most Hospitals in Portugal have an 
office dedicated to support clinical research (as a govern-
ment decision from 2015) [9]—but only a few can support 
physicians in the design or implementation of more complex 
clinical trials involving IMPs or medical devices, or even 
provide support to prepare proposals for national or interna-
tional funding. The concept of academic clinical trial units 
(CTU) introduced in these two countries by ECRIN has been 
valuable to support clinical investigators and multinational 
IICTs [9], in the conduct of IICTs, especially in IMPs and/
or medical devices trials, during all phases of the process 
Table 1  National and International Funding Agencies and Programs in Czech Republic in and Portugal and Respective Number of Funded Tri-
als. (Nº = Number of Clinical Trials Funded by the Respective Funding Organization/Program).
Funders Czech Republic Portugal
National Funding Agencies/Funding 
Programs
Internal Grant Agency of the Czech Ministry of Health (IGA until 
2014); Currently AZV (Czech Health Research Council)
61 –
Charles University Research Fund 10 –
Fundação para a Ciência e Tecnologia (FCT) – 27
National Structural funding (COMPETE, PRODEP) – 2
ARDITI – Agência Regional para o Desenvolvimento da Investi-
gação
– 1
International Funding Agencies/ 
Funding Programs
European Commission (includes H2020, IMI, Erasmus Program) 18 17
Canadian Institutes of Health Research (Canada) 7 0
European Regional Development Fund 6 0
Medical Research Council (UK) 7 2
Australian National Health Service and Medical Research Council 0 5
National Institutes of Health (NIH, USA) 0 3
EEA Grants 0 1
Carlos III Institute of Health (Spain) 0 2
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(from the idea until the close out). Universities and biomedi-
cal research institutes in Portugal detected earlier the need 
of professional supporting offices to prepare and manage 
national and international research projects.
National Policies for Clinical Research
Both countries present national public policies implemented 
(or not) for clinical research, in particularly IICTs, which 
are summarized in Table 2. The data were collected from 
national legal decisions, analysis of the call’s eligibility cri-
teria for funding national infrastructures and projects as well 
as higher education institutions in each country.
There have been legal decisions to establish clinical 
research as a priority that included the membership of 
ECRIN-ERIC and the definition of the clinical investigator 
status in both countries [10–15]. Since 2015, ten trials were 
initiated by ECRIN and conducted in the Czech Republic 
in this time period: POEM_H2020, FAIRPARK II_H2020, 
NISCI_H2020, SECURE_H2020, EuroHYP_7FP, PrOOf_
H2020, VISION_DMD_H2020, DISCHARGE_FP7, 
PopART_H2020, TENSION_H2020. Some of these pro-
jects were also conducted in Portugal (FAIR PARK II, 
DISCHARGE and POPART). Besides these, the projects 
MACUSTAR_IMI, BETA3LVH_H2020 and HCQ4Surfe-
defect_ERA-NET, were also conducted in Portugal making 
a total of 6 trials initiated in the country through ECRIN. In 
both countries, none of these trials were from the initiative 
of national investigators.
The Internal Grant Agency (IGA) of the Ministry of 
Health supporting medical research and development 
was established in 1990 in Czech Republic and has been 
replaced by Czech health research council, AZV, founded 
on 01/04/2014 [19, 20]. This council, launch calls each year 
and supports the selected applications of clinical research 
in the different medicine areas. The establishing the AZV 
and defining the national priorities of oriented research, 
experimental development and innovations are the long-term 
strategies of the Czech government to support the clinical 
research in medicine. Nevertheless, to our best knowledge 
in the Czech Republic, the higher education courses specific 
to train clinical trials professionals are being prepared. In 
Portugal, the national government supported and invested 
in specific training for medical  doctors14 and research team 
professionals from hospitals [16].
The investment of the Portuguese government, public and 
private universities in post-graduation courses, including the 
Portugal Clinical Scholars Research Training (PTCSRT) 
[17] and the Clinical Investigator Certificate, CLIC [16] is 
an asset to trigger a high-quality clinical investigation. How-
ever, strategies to allocate research time to clinical investiga-
tors still need to be implemented [11].
To share knowledge and resources in 2016 a Portuguese 
government decision created the concept of Clinical Aca-
demic Centers (CAC)—joining hospitals, universities and 
research institutes around a medical school [13]. Currently, 
9 CACs are officially established in Portugal, however, they 
are still deciding on the respective organizational strategy. 
In line with what is established in the Czech Republic since 
2004, in Portugal a new agency to fund exclusively clini-
cal research studies: Agência para a Investigação Clínica e 
Investigação Biomédica (AICIB), focusing on translational 
medicine products trials, was launched in 2018 but is not yet 
operational [18].
Clinical Trials Published in Peer‑Reviewed Scientific 
Journals
In the Czech Republic, there are 41% of published trials 
among the 180 completed (n = 73/180) while in Portugal, 
from the 144 completed trials, 55% (n = 79/144) are pub-
lished in peer-reviewed journals (Fig. 1, step 7). In the 
Czech Republic, a higher percentage of published studies 
focus on IMPs (44%, n = 32/73), followed by surgery and 
procedures (32%, n = 23/73). On the other hand, in Portugal, 
Table 2  National Public 
Policies Implemented by 
the Portuguese and Czech 
Governments Involved in or to 
Promote Clinical Research.
ECRIN-ERIC European Clinical Research Infrastructure Network-European Research Infrastructure Con-
sortium
a A national agency (AICIB) for clinical research funding is now implemented in Portugal [18]
b A course dedicated to clinical trials management is under preparation
Public Policies Czech Republic Portugal
Establish clinical research as a priority Yes [10] Yes [11–13]
Be member of ECRIN-ERIC Yes [14] Yes [13]
Define a legal specific status for clinical investigators Yes [15] Yes [11]
Investment in public infrastructures to promote/support IICTs Yes No
Specific and periodic funding for IICT Yes No
National funding agency specific for health research Yes Noa
National public initiatives for clinical research team’s capacitation Nob Yes [16, 17]
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most publications focus on behavior studies (37%, n = 29/79) 
followed by IMPs (32%, n = 25/79) (Fig. 4a).
The impact factor (IF) of the journal where these IICTs 
were published varies widely between 0 to 72 as shown in 
Fig. 4b. Thirty percent (30%, n = 23/73) of the trials per-
formed in the Czech Republic with publications were pub-
lished in journals with IF between 6 to 20. Around 75% 
(n = 59/79) of published papers with trials involving Por-
tuguese organizations, have an IF below 5 and only 16% 
(n = 13/79) were published in journals with IF above 20. The 
average IF of all these journals is similar for both countries 
and is around 9. The total number of citations of papers 
published in Czech Republic and in Portugal up to 1 year 
after publication were, 458 and 417, respectively (Fig. 4b).
Portuguese investigators are authors/co-authors of 15% 
(n = 2/13) of the papers published in journals with IF > 20, 
conversely to what is observed with Czech investigators 
who authored/co-authored of 75% (n = 6/8) of the papers 
published in high impact factor journals (Inset B1, Fig. 4b). 
Furthermore, international funding agencies funded 50% 
(n = 4/8) of trials in the Czech Republic and only 31% 
(n = 4/13) in Portugal that were published in journals with 
IF > 21 (Inset B1, Fig. 4b). None of these published tri-
als in high impact journals was funded by the Portuguese 
national funding agency while in the Czech Republic, one 
of these trials was funded by the national funding agency. 
Around half of the trials published in journals with IF > 21 
are funded by private funders in Portugal (54%, n = 7/13) 
and around 38% (n = 3/8) in the Czech Republic. Addition-
ally, most of these published trials were multinational and 
focused in IMPs, in both countries.
According to our results the Czech Republic might have 
had a better return of the investment in this field, publishing 
a higher number of publications in journals with IF above 
6 compared with Portugal (n = 32 vs n = 20), with a higher 
number of citations when compared to those published in 
Portugal. When compared to the Czech Republic, Portugal 
has slightly a higher number of published completed tri-
als and a higher number of publications in journals with IF 
greater than 21 (n = 13 vs n = 8), but the participation of Por-
tuguese recruiting sites does not correspond to more author-
ships of Portuguese investigators in the publication since 
Figure  4  IICTs Published in Peer-Reviewed Journals According to 
the Type of Intervention (a) and Impact Factor of the Journals and 
Paper Citations Up to 1 Year After Publication (b). Papers published 
in 2018 were not considered. Inset of B (B1): clinical trials published 
in journals with impact factor higher than 21. * Includes national and 
international funding agencies.
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only 15% of these publications have Portuguese authors, 
whereas 75% of publications with the involvement of the 
Czech Republic recruiting sites have national investigators 
as authors. The values above mentioned might be under-
estimated because in this work, only studies registered in 
CTR and the first publication with results of each completed 
IICTs were considered.
Discussion
In this study, a systematic search of IICTs registered in four 
CTRs was conducted with the main goal of comparing the 
type of studies, main funders and scientific output in the 
Czech Republic and in Portugal. The methodology used in 
this work, allowed us for the first time to have a picture 
of IICTs in two European countries with similar GDP and 
population, HDI and number of medical schools, collecting 
information both from CTRs and publications.
Globally we found a better performance of the Czech 
Republic in terms of higher number of IICTs, including 
those with IMPs, of papers published in higher impact fac-
tor’s journals, citations, and publication with more national 
authorships, when compared with Portugal. These find-
ings suggest that a funding agency more focused in clini-
cal research as the Czech Republic funding agency, may 
facilitate the authorship of national investigators in clinical 
research studies with higher quality.
In both countries, only a small percentage of the national 
organizations were sponsoring multinational IICTs in the 
Czech Republic (6%) and in Portugal (4%), in line with pre-
vious reports, where only 3% of all IICTs in the International 
Clinical Trials Registry Platform (ICTRP) are international 
[21]. The existence of national funding grant agencies is of 
major relevance to implement pilot IICTs that later could be 
escalated to the European level.
The national governments and European Commission 
investment in clinical research infrastructures have been criti-
cal for the development of this area [22, 23]. Both, the Czech 
Republic and Portugal governments have been investing in 
European infrastructures of clinical research such as ECRIN-
ERIC. However, while in the Czech Republic the government 
also invested in the national network of CTUs, in Portugal the 
investment was limited to the ECRIN-ERIC membership fee. 
Recently a positive discrimination for clinical research has 
been introduced in the Portuguese infrastructures’ roadmap 
national strategy [24]. As referred in a previous publication 
by the same authors, Germany, France, and the UK are good 
examples to show the increase in the number of IICTs after 
the investment of respective governments in both the funding 
of IICTs and supporting infrastructures [4].
When compared to other European countries, Czech 
Republic and Portugal are below the average both in the num-
ber of IICTs/million of citizens and % IICT/total CT [4]. 
Considering the recent governmental strategies it is clear that 
this is a work in progress, worthwhile to follow and assess in 
upcoming years. It would be worth following the example of 
countries like Denmark (Innovation Fund Denmark) [25] or 
the UK [26] who establish new rules to support the funding 
of multinational clinical trials by their national grant agen-
cies. On the other hand, the recent governmental initiatives in 
Czech Republic and in Portugal to stimulate clinical research 
might serve as an example for those countries with lower 
number of IICTs identified in previous publications such as 
Slovakia and Poland [4, 21]. Additionally, if other countries 
publish their report assessment on clinical research perfor-
mance it would facilitate the comparison and extrapolation 
among European countries policies and outcomes.
The relevance and impact of IICTs for the continuous 
improvement of therapies and the development of new pub-
lic policies rely on the results’ independence from the inter-
ests of any other stakeholders [27]. Therefore, it is critical 
for the countries to promote IICTs through a comprehensive 
and stimulating set of public policies and funding. For exam-
ple, Italian government decided to invest on IICTs funding, 
through the Italian Medicines Agency (AIFA) that resulted in 
an increase of the number of independent clinical research and 
scientific outputs [28, 29]. This initiative started in 2005 and 
an amount of 40 M€/year have been provided by the industry 
to AIFA, to fund competitive IICTs projects developed by 
Italian physicians working in the public/non-profit sector [29].
As a limitation of this study, the number of IICTs with 
IMPs in both countries might be underestimated due to lack 
of registration and/or misclassification, although being man-
datory [30, 31]. Similar underestimation might also have 
occurred in the registration of the other type of interven-
tional studies since these are not mandatory in both coun-
tries. Nevertheless, with this work, we expect to reinforce 
the need of registration of all types of clinical studies, in 
particularly those funded by national funding agencies. This 
would facilitate the tracking of the studies in which a huge 
investment was made, as well as the assessment of the out-
comes in terms of publications, guidelines, etc.
In our view, the development of clinical research relies in 
a national strategy that gather health authorities with science, 
innovation and economy stakeholders. A change in the way 
health care units’ value clinical research outcomes and how 
their performance is evaluated and rewarded, requires a new 
paradigm. We expect that this work has unveiled the need 
to explore further details on the IICT quality and funding in 
other European countries and to learn with those that might 
have implemented effective indicators to monitor their perfor-
mance in this particular type of research.
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Conclusions
For the first time, two European Countries were compared 
in terms of the number of IICTs, funders and the respec-
tive scientific outcome. Our results showed that in the same 
timeframe, the Czech Republic has higher number of regis-
tered IICTs and higher number of publications with Czech 
authors in top journals (impact factors > 21) when compared 
to Portugal. These findings might be related to the existence 
of specific and periodic funding for clinical research in the 
Czech Republic, although the factors behind this difference 
are difficult to unravel with the methodological approach in 
this study. We anticipate using the results of this study as 
a baseline to the better appraisal of IICTs evolution in the 
upcoming years and inspire other countries to do the same 
type of evaluation.
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